title: Containment of carbapenem resistance rates of Klebsiella pneumoniae and Acinetobacter baumannii in a Greek hospital with a concomitant increase in colistin, gentamicin and tigecycline resistance.
abstract: In 2010 the Hellenic center for disease control and prevention launched the "Prokroustes" nationwide action plan to tackle the increasing rates of carbapenem resistance among gram-negative nosocomial pathogens. In the present report, data from a Greek tertiary-care hospital are presented three years after the adoption of the infection control measures. Carbapenem resistance rates have been contained for Klebsiella pneumoniae and Acinetobacter baumannii but not for Pseudomonas aeruginosa. More worryingly, in accordance with their overuse against carbapenem-resistant bacteria, resistance rates to colistin and tigecycline have risen significantly.
authors.affiliation: Department of Clinical Microbiology, St. Paul General Hospital of Thessaloniki, Greece.
authors.forename: Georgios
authors.initials: G
authors.lastname: Meletis
authors.affiliation: Department of Clinical Microbiology, St. Paul General Hospital of Thessaloniki, Greece.
authors.forename: Efstathios
authors.initials: E
authors.lastname: Oustas
authors.affiliation: Department of Clinical Microbiology, St. Paul General Hospital of Thessaloniki, Greece.
authors.forename: Christina
authors.initials: C
authors.lastname: Botziori
authors.affiliation: Department of Clinical Microbiology, St. Paul General Hospital of Thessaloniki, Greece.
authors.forename: Eleni
authors.initials: E
authors.lastname: Kakasi
authors.affiliation: Department of Clinical Microbiology, St. Paul General Hospital of Thessaloniki, Greece.
authors.forename: Asimoula
authors.initials: A
authors.lastname: Koteli
mesh_terms: D000151:Acinetobacter Infections / Q000453:epidemiology / Q000382:microbiology*; D040981:Acinetobacter baumannii / Q000187:drug effects* / Q000235:genetics / Q000302:isolation & purification; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D015780:Carbapenems / Q000494:pharmacology; D003091:Colistin / Q000494:pharmacology; D003264:Containment of Biohazards / Q000706:statistics & numerical data; D003428:Cross Infection / Q000453:epidemiology / Q000382:microbiology*; D024901:Drug Resistance, Multiple, Bacterial; D005839:Gentamicins / Q000494:pharmacology; D006115:Greece / Q000453:epidemiology; D006801:Humans; D007710:Klebsiella Infections / Q000453:epidemiology / Q000382:microbiology*; D007711:Klebsiella pneumoniae / Q000187:drug effects* / Q000235:genetics / Q000302:isolation & purification; D008826:Microbial Sensitivity Tests; D008911:Minocycline / Q000031:analogs & derivatives / Q000494:pharmacology; D062606:Tertiary Care Centers / Q000706:statistics & numerical data; D000078304:Tigecycline
chemical_list: D000900:Anti-Bacterial Agents; D015780:Carbapenems; D005839:Gentamicins; D000078304:Tigecycline; D008911:Minocycline; D003091:Colistin
keywords: Carbapenems; Colistin; Infection control; Tigecycline